Objective We attempted to evaluate the feasibility (therapeutic efficacy, tolerance, and
clinical courses after treatment) of pirfenidone, an anti-fibrotic drug for patients with chronic …

Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of
idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low …

Objective Long-term effects of pirfenidone have been poorly understood to date. This study
investigated the clinical efficacy and safety of long-term pirfenidone use for idiopathic …

Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

Background Pirfenidone is an oral antifibrotic agent that has been shown to reduce the
decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an …

Background Pirfenidone is a novel anti-fibrotic drug that has shown efficacy in five
randomized multicenter clinical trials enrolling patients with Idiopathic Pulmonary Fibrosis of …

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective
therapy. A multicentre, double-blind, placebo-controlled, randomised phase III clinical trial …

Background and objective Pirfenidone is an oral antifibrotic agent that is approved in several
countries for the treatment of idiopathic pulmonary fibrosis (IPF). We performed a …

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease. Although
the precise cause of the disease is still unknown, recent studies have shown that the …

Idiopathic pulmonary fibrosis (IPF) is a progressive clinical syndrome of unknown etiology
and fatal outcome. Currently available therapies are ineffective and associated with …